WHO ICTRP trial
A prospective, open-labelled, randomized, multicenter phase II study to evaluate…
ChiCTR-TRC-12002466 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-TRC-12002466 |
|---|---|
| Public title | A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation IIIA NSCLC patients with EGFR 19 or 21 exon mutation |
| Scientific title | A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation NSCLC patients with EGFR19 or 21 exon mutation |
| Primary sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | II (Phase II study) |
| Countries | China |
| Conditions | NSCLC |
| Interventions | Erlotinib:Erlotinib 150mg daily oral up to 2 years;NP Chemotherapy:NP Chemotherapy |
| Registration date | Aug 28, 2012 |
| Target size | Erlotinib:47;NP Chemotherapy:47 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: